COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192, [...]
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the [...]
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
02/03/2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
Cytokinetics to Participate in March Investor Conferences
02/03/2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/03/2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
02/03/2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
02/03/2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled [...]
RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026
02/03/2026
LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Filing of the 2025 Universal Registration Document
02/03/2026
Press release 2 March 2026 Information on the availability of the 2025 Universal Registration Document Paris, 2 March 2026 – Clariane (CLARI - ISIN: FR0010386334) announces the release of its 2025 Universal Registration [...]
Mise à disposition du Document d’enregistrement universel 2025
02/03/2026
Communiqué de presse Information relative à la mise à disposition du Document d’enregistrement universel 2025 Paris, le 2 mars 2026 : Clariane (CLARI - ISIN : FR0010386334) annonce la publication de son Document d’ [...]
IBA – ACQUISITION OF OWN SHARES
02/03/2026
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 2 nd , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion [...]
IBA – ACQUISITION D’ACTIONS PROPRES
02/03/2026
Louvain-la-Neuve, Belgique, 2 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
EssilorLuxottica: Disclosure of transactions in own shares
02/03/2026
Disclosure of transactions in own shares Paris, France (March 2, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]
Valneva annonce sa participation à des conférences investisseurs
02/03/2026
Lyon (France), le 2 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et [...]
Valneva to Participate in Upcoming Investor Conferences
02/03/2026
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in [...]
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
02/03/2026
Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no milestone associated [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
02/03/2026
Déclaration de transactions sur actions propres Paris, France (2 mars 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 27 février 2026, les [...]

Pages